Abbas Hussain Joins Moderna's Board of Directors
Moderna (NASDAQ:MRNA) has announced the appointment of Abbas Hussain to its Board of Directors, effective October 2, 2024. Hussain, the former CEO of Vifor Pharma, brings over 35 years of commercial leadership and operating experience in healthcare. His background includes serving as Global President of GSK, Pharmaceuticals and Vaccines, providing significant global vaccine commercialization experience in emerging and mature markets.
Moderna's leadership, including Chairman Noubar Afeyan and CEO Stéphane Bancel, expressed enthusiasm about Hussain's addition to the board, citing his strategic insights and global operational expertise as valuable assets for the company's continued growth and innovation. Hussain's extensive experience is expected to strengthen Moderna's commercial organization and support the launch of innovative products.
Moderna (NASDAQ:MRNA) ha annunciato la nomina di Abbas Hussain al suo Consiglio di Amministrazione, con decorrenza dal 2 ottobre 2024. Hussain, ex CEO di Vifor Pharma, porta con sé oltre 35 anni di esperienza nella leadership commerciale e operativa nel settore sanitario. Il suo background include il ruolo di Presidente Globale di GSK, Farmaceutici e Vaccini, fornendo un'importante esperienza globalmente nella commercializzazione di vaccini sia in mercati emergenti che maturi.
La leadership di Moderna, compresi il Presidente Noubar Afeyan e il CEO Stéphane Bancel, ha espresso entusiasmo riguardo all'aggiunta di Hussain al consiglio, citando le sue intuizioni strategiche e la sua esperienza operativa globale come risorse preziose per la crescita e l'innovazione continua dell'azienda. Si prevede che l'ampia esperienza di Hussain rafforzi l'organizzazione commerciale di Moderna e sostenga il lancio di prodotti innovativi.
Moderna (NASDAQ:MRNA) ha anunciado el nombramiento de Abbas Hussain a su Junta Directiva, efectivo el 2 de octubre de 2024. Hussain, ex CEO de Vifor Pharma, aporta más de 35 años de experiencia en liderazgo comercial y operativo en el sector de la salud. Su trayectoria incluye haber sido Presidente Global de GSK, Farmacéuticos y Vacunas, aportando una significativa experiencia en la comercialización global de vacunas en mercados emergentes y maduros.
El liderazgo de Moderna, incluido el Presidente Noubar Afeyan y el CEO Stéphane Bancel, expresó entusiasmo por la incorporación de Hussain al consejo, citando sus conocimientos estratégicos y su experiencia operativa global como activos valiosos para el crecimiento y la innovación continuos de la empresa. Se espera que la amplia experiencia de Hussain fortalezca la organización comercial de Moderna y apoye el lanzamiento de productos innovadores.
모더나 (NASDAQ:MRNA)는 압바스 후세인을 이사회에 임명했다고 발표했으며, 이는 2024년 10월 2일부터 효력이 발생합니다. 후세인은 바이포르 파마의 전 CEO로, 의료 분야에서 35년 이상의 상업적 리더십 및 운영 경험을 보유하고 있습니다. 그의 배경은 GSK 글로벌 의약품 및 백신 회장으로서, 신흥 시장과 성숙한 시장에서의 백신 상업화 경험을 제공합니다.
모더나의 리더십은 의장 노우바르 아페얀과 CEO 스테판 반셀을 포함하여 후세인의 이사회 합류에 대한 열정을 표현하며, 그의 전략적 통찰력과 글로벌 운영 전문성이 회사의 지속적인 성장과 혁신을 위한 귀중한 자산이라고 언급했습니다. 후세인의 폭넓은 경험은 모더나의 상업 조직을 강화하고 혁신적인 제품 출시를 지원할 것으로 기대됩니다.
Moderna (NASDAQ:MRNA) a annoncé la nomination de Abbas Hussain à son Conseil d'Administration, prenant effet le 2 octobre 2024. Hussain, l'ancien PDG de Vifor Pharma, apporte plus de 35 ans d'expérience en leadership commercial et opérationnel dans le secteur de la santé. Son parcours comprend le poste de Président Global de GSK, Médicaments et Vaccins, offrant une expérience significative dans la commercialisation mondiale des vaccins sur les marchés émergents et matures.
La direction de Moderna, dont le Président Noubar Afeyan et le PDG Stéphane Bancel, a exprimé son enthousiasme quant à l'ajout de Hussain au conseil, citant ses idées stratégiques et son expertise opérationnelle mondiale comme des atouts précieux pour la croissance continue et l'innovation de l'entreprise. On s'attend à ce que l'expérience approfondie de Hussain renforce l'organisation commerciale de Moderna et soutienne le lancement de produits innovants.
Moderna (NASDAQ:MRNA) hat die Ernennung von Abbas Hussain in seinen Vorstand bekannt gegeben, gültig ab dem 2. Oktober 2024. Hussain, ehemaliger CEO von Vifor Pharma, bringt über 35 Jahre an kommerzieller Führung und Betriebserfahrung im Gesundheitswesen mit. Sein Hintergrund umfasst die Rolle des globalen Präsidenten von GSK, Pharmazeutika und Impfstoffe, was umfassende globale Erfahrung in der Vermarktung von Impfstoffen in aufstrebenden und reifen Märkten mit sich bringt.
Die Führung von Moderna, einschließlich des Vorsitzenden Noubar Afeyan und des CEO Stéphane Bancel, äußerte sich begeistert über Hussains Ergänzung des Vorstands und hob seine strategischen Einblicke und globalen Betriebsexpertise als wertvolle Vermögenswerte für das kontinuierliche Wachstum und die Innovation des Unternehmens hervor. Hussains umfangreiche Erfahrung wird voraussichtlich die kommerzielle Organisation von Moderna stärken und die Einführung innovativer Produkte unterstützen.
- Addition of Abbas Hussain to the Board of Directors brings 35+ years of healthcare leadership experience
- Hussain's global vaccine commercialization expertise aligns with Moderna's expansion efforts
- Strategic insights and operational expertise expected to drive company growth and innovation
- None.
Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor Pharma
As former Global President of GSK, Pharmaceuticals and Vaccines, Hussain brings significant global vaccine commercialization experience in emerging and mature markets, along with significant Board of Directors expertise
CAMBRIDGE, MA / ACCESSWIRE / October 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Abbas Hussain, former Chief Executive Officer of Vifor Pharma, has joined Moderna's Board of Directors, effective October 2, 2024.
"As Moderna accelerates our global commercialization efforts, Abbas is a tremendous addition to our Board," said Noubar Afeyan, Co-Founder and Chairman of Moderna. "With decades of leadership in vaccines and pharmaceuticals across both mature and emerging markets, Abbas brings invaluable strategic insights and global operational expertise. We are excited to welcome him and look forward to benefiting from his experience as we drive continued growth and innovation."
"I am honored to join the Board of Directors at Moderna, a company that is at the forefront of groundbreaking medical innovations," said Abbas Hussain. "Moderna's pioneering research and its expanding global presence have already made a profound impact on public health worldwide. I am excited to contribute to its future, confident that even greater advancements lie ahead."
"As we advance our mission to deliver the greatest possible impact to people through mRNA medicines, Abbas's more than 35 years of leadership in healthcare will be invaluable as we continue to strengthen our commercial organization and launch innovative products," said Stéphane Bancel, Chief Executive Officer of Moderna. "We are fortunate to welcome Abbas to the Moderna Board, and I look forward to collaborating closely with him."
Mr. Hussain most recently served as Chief Executive Officer of Vifor Pharma from 2021 to 2023. Prior to that, he served in various leadership roles at GlaxoSmithKline, most recently as Global President, Pharmaceuticals and Vaccines. Earlier in his career, Mr. Hussain held various global leadership roles at Eli Lilly and Company.
Mr. Hussain currently holds various non-executive director and advisory roles, including Chairman of Asceneuron SA, Director for Mallinckrodt Pharmaceuticals and Alfasigma SpA, and Advisor to 4Bio Capital. He previously served on the boards of Cochlear Limited, CSL, Teva Pharmaceutical and Immunocore.
Mr. Hussain holds a BSc from the Loughborough Institute of Technology.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
###
Moderna Contacts
Media:
Chris Ridley
Head, Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
FAQ
When did Abbas Hussain join Moderna's Board of Directors?
What is Abbas Hussain's background in the pharmaceutical industry?
How is Abbas Hussain expected to contribute to Moderna (MRNA)?
What other board positions does Abbas Hussain currently hold?
